Compass Therapeutics (CMPX) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Precision BioSciences (DTIL) has outperformed Compass Therapeutics (CMPX) over the past year, gaining 10.0% versus a loss of 71.7%. Over five years, CMPX leads with a -68.2% price change compared with -97.9% for DTIL. Precision BioSciences is the larger company by market cap ($177.8 million vs $176.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CMPX | DTIL |
|---|---|---|
| Share price | $0.981 | $6.44 |
| Market cap | $176.67M | $177.75M |
| 1-day change | -3.82% | +3.04% |
| YTD return | -81.01% | +50.24% |
| 1-year return | -71.75% | +10.04% |
| 5-year return | -68.22% | -97.87% |
| EPS (TTM) | $-0.39 | $-1.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.88 | $9.62 |
| 52-week low | $0.829 | $3.53 |
| Distance from 52-week high | -85.74% | -33.06% |
| Analyst consensus | buy | none |
| Avg. price target upside | +455.56% | +356.52% |
| Average volume | 4.06M | 293.42K |
| Shares outstanding | 180.09M | 27.60M |
| Employees | 39 | 67 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed CMPX by 81.8 percentage points over the past year.
About Compass Therapeutics
CMPX stock →Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 39 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 67 employees
CMPX vs DTIL FAQ
Which is bigger, Compass Therapeutics or Precision BioSciences?
Precision BioSciences (DTIL) is larger, with a market capitalization of $177.75M compared with $176.67M for Compass Therapeutics (CMPX).
Which stock has performed better over the past year, CMPX or DTIL?
DTIL returned +10.04% over the past 12 months, compared with -71.75% for CMPX (price return, excluding dividends). Past performance does not predict future results.
Are Compass Therapeutics and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.